Bristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to...
Thursday, August 2, 2012, 8:49 AM ETBristol-Myers Squibb (BMY) -5.2% premarket after it suspends its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure, raising questions about the drug's potential and the $2.5B it paid earlier this year to buy the company that developed it. Companies that could benefit from BMY's woes: GILD +8.8%, IDIX +8.2% premarket.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles